Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and

Premier, Inc. to Report Fiscal 2021 Fourth-Quarter and Full-Year Results and Host Conference Call on August 17, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2021 Fourth-Quarter and Full-Year Results and Host Conference Call on August 17, 2021


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 fourth quarter and full year on Tuesday, August 17, 2021, at approximately 6:30 a.m. EDT. The

Novocure to Report Second Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Report Second Quarter 2021 Financial Results


Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management

Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer


Novocure (NASDAQ: NVCR) today announced final results from its phase 2 pilot HEPANOVA trial in liver cancer testing the safety and efficacy of Tumor Treating Fields (TTFields) together with

Bronson Healthcare Partners With Acadia Healthcare to Build New Behavioral Health Hospital to Serve Southwest Michigan: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Bronson Healthcare Partners With Acadia Healthcare to Build New Behavioral Health Hospital to Serve Southwest Michigan


Bronson Healthcare and Acadia Healthcare Company announced today that they have formed a joint venture to build a 96-bed inpatient behavioral health facility in Battle Creek, Michigan. Together

Acadia Healthcare Forms Joint Venture with Bronson Health to Build a New Behavioral Health Facility in Southwest Michigan: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture with Bronson Health to Build a New Behavioral Health Facility in Southwest Michigan


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Bronson Healthcare, one of Michigan’s leading, integrated healthcare systems. The new

Premier Inc. Honors Florida Nonprofit Dedicated to Fighting Food Insecurity With National Award and $100,000 Prize: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Honors Florida Nonprofit Dedicated to Fighting Food Insecurity With National Award and $100,000 Prize


Community Enhancement Collaboration, Inc. (CEC), a nonprofit dedicated to eradicating food insecurity in Broward County, Florida, has received the 28th annual Monroe E. Trout Premier Cares Award

Atrium Health Recognized for Innovation, High-Quality Healthcare by Premier Inc.: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Atrium Health Recognized for Innovation, High-Quality Healthcare by Premier Inc.


Premier Inc., a leading healthcare improvement company, (NASDAQ: PINC) has named Atrium Health, an integrated, nonprofit health system serving the Carolinas and Georgia, the winner of the 2021

Novocure Initiates Usability Study for Flexible Torso Array: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Initiates Usability Study for Flexible Torso Array


Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four

Xencor to Present at the Jefferies Virtual Healthcare Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the Jefferies Virtual Healthcare Conference


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Acadia Healthcare to Participate in the Jefferies Virtual Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in the Jefferies Virtual Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Jefferies Virtual Healthcare Conference, which takes place June 1 – June 4, 2021. There will

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma


Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT

Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement

Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Xencor Reports First Quarter 2021 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports First Quarter 2021 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

Premier Inc. to Participate in BofA Securities Virtual 2021 Healthcare Conference on May 11, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. to Participate in BofA Securities Virtual 2021 Healthcare Conference on May 11, 2021


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the BofA Securities

Acadia Healthcare to Participate in the BofA Securities 2021 Healthcare Conference and the 2021 RBC Capital Markets Global Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in the BofA Securities 2021 Healthcare Conference and the 2021 RBC Capital Markets Global Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two upcoming virtual healthcare conferences.



On Thursday, May 13, 2021, the Company will

Premier, Inc. Reports Fiscal-Year 2021 Third-Quarter Results and Raises Fiscal Year 2021 Guidance: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2021 Third-Quarter Results and Raises Fiscal Year 2021 Guidance


Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2021 third quarter ended March 31, 2021 and raised its fiscal 2021 financial guidance.



"I am excited to take

Acadia Healthcare Reports First Quarter 2021 Results and Increases 2021 Guidance: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports First Quarter 2021 Results and Increases 2021 Guidance


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2021.



First Quarter 2021 Results



The Company reported revenue of $551.2

Novocure Reports First Quarter 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven